Document is current
Any future updates will be listed below
-
Authors
Nahmad, Alessio D. https://orcid.org/0000-0001-6104-577X
Lazzarotto, Cicera R. https://orcid.org/0000-0003-1093-0175
Zelikson, Natalie
Kustin, Talia https://orcid.org/0000-0001-5677-4150
Tenuta, Mary https://orcid.org/0000-0002-0708-3932
Huang, Deli https://orcid.org/0000-0002-6989-639X
Reuveni, Inbal
Nataf, Daniel
Raviv, Yuval
Horovitz-Fried, Miriam
Dotan, Iris
Carmi, Yaron https://orcid.org/0000-0002-0972-0616
Rosin-Arbesfeld, Rina https://orcid.org/0000-0002-4216-2425
Nemazee, David https://orcid.org/0000-0002-4769-6311
Voss, James E. https://orcid.org/0000-0002-4777-1596
Stern, Adi
Tsai, Shengdar Q. https://orcid.org/0000-0001-9161-3993
Barzel, Adi https://orcid.org/0000-0001-8490-7002
- License Information
-
More Information
Article History
Received: 15 February 2021
Accepted: 22 April 2022
First Online: 9 June 2022
Competing interests
: A.D.N., D. Nataf, M.H.-F., I.D. and A.B. are listed as inventors on patent applications covering B cell engineering. A.D.N. and A.B. have an equity stake in and receive monetary compensation from Tabby Therapeutics Ltd, a B cell engineering company. S.Q.T. is a coinventor on patents covering the CHANGE-seq method. S.Q.T. is a member of the scientific advisory boards of Kromatid, Inc. and Twelve Bio. The other authors declare no competing interests.
